secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMPEL PHARMACEUTICALS INC (—)
CIK:        0001445499
Form:       8-K
Filed at:   2023-09-07T23:59:59+00:00
Accession:  0000950170-23-047013
Event type: debt
Sentiment:  negative
Materiality: 0.85
Item codes: 1.01, 2.03, 3.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Impel restructures debt with $121.5M amended credit facility, $0.01 warrants, director Shah resigns
--------------------------------------------------------------------------------

- Total loan amount of ~$121.5M: $20M new tranche B term loans, $96.5M of existing debt exchanged, plus $5.0M forbearance fee.
- Warrants for up to 4,749,800 shares of common stock at $0.01 per share; 1,781,175 issued at closing; 2,968,625 more contingent on additional tranche B draws.
- Interest rate SOFR + 10.75% (PIK through Dec 31, 2023). First lien tranche B entitled to 2x multiple on invested capital.
- Director Dr. Mahendra G. Shah resigned from board effective immediately; resignation not due to any disagreement.
- Management Incentive Plan approved: 0.85% of net cash consideration in a corporate transaction allocated to specified executives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1445499/000095017023047013/0000950170-23-047013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1445499/000095017023047013/impl-20230831.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-047013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer